• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

50 岁及以上成年人中与 THC 相关的神经精神症状评估：系统评价和荟萃回归分析。

Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.

机构信息

Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, Division of Academic Psychiatry, King's College London, London, United Kingdom.

Department of Psychosis, Institute of Psychiatry, Psychology, and Neuroscience, Division of Academic Psychiatry, King's College London, London, United Kingdom.

出版信息

JAMA Netw Open. 2021 Feb 1;4(2):e2035913. doi: 10.1001/jamanetworkopen.2020.35913.

DOI:10.1001/jamanetworkopen.2020.35913
PMID:33528550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7856542/
Abstract

This systematic review and metaregression analysis estimates the association between the delta-9-tetrahydrocannabinol (THC) dose of cannabinoid-based medicines and neuropsychiatric adverse events among adults aged 50 years and older.

摘要

这篇系统评价和荟萃回归分析估计了大麻素类药物中 Δ9-四氢大麻酚 (THC) 剂量与 50 岁及以上成年人神经精神不良事件之间的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7131/7856542/11a5a542a80e/jamanetwopen-e2035913-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7131/7856542/be63505c6524/jamanetwopen-e2035913-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7131/7856542/11a5a542a80e/jamanetwopen-e2035913-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7131/7856542/be63505c6524/jamanetwopen-e2035913-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7131/7856542/11a5a542a80e/jamanetwopen-e2035913-g002.jpg

相似文献

1
Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.50 岁及以上成年人中与 THC 相关的神经精神症状评估：系统评价和荟萃回归分析。
JAMA Netw Open. 2021 Feb 1;4(2):e2035913. doi: 10.1001/jamanetworkopen.2020.35913.
2
Cannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use.使用δ-8四氢大麻酚继发的大麻素呕吐综合征。
Am J Med. 2021 Dec;134(12):e582-e583. doi: 10.1016/j.amjmed.2021.06.048. Epub 2021 Jul 31.
3
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.大麻素用于接受化疗的成年癌症患者的恶心和呕吐治疗。
Cochrane Database Syst Rev. 2015 Nov 12;2015(11):CD009464. doi: 10.1002/14651858.CD009464.pub2.
4
Cannabis-based medicinal products: summary of NICE guidance.基于大麻的医药产品：英国国家卫生与临床优化研究所指南总结
BMJ. 2020 Apr 21;369:m1108. doi: 10.1136/bmj.m1108.
5
Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.在欧洲，用于慢性疼痛管理和姑息/支持性治疗的基于大麻的药物的可及性和批准情况：对欧洲疼痛联合会各章节现状的调查。
Eur J Pain. 2018 Mar;22(3):440-454. doi: 10.1002/ejp.1147. Epub 2017 Nov 13.
6
Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer.多国癌症支持治疗协会（MASCC）关于癌症患者胃肠道症状使用大麻素的专家意见/共识指南。
Support Care Cancer. 2022 Dec 16;31(1):39. doi: 10.1007/s00520-022-07480-x.
7
Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.口服大麻素预防化疗引起的恶心和呕吐：系统评价和荟萃分析。
Support Care Cancer. 2020 May;28(5):2095-2103. doi: 10.1007/s00520-019-05280-4. Epub 2020 Jan 8.
8
A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting.一项关于纳布啡与安慰剂治疗化疗引起的恶心和呕吐的多机构III期研究。
Cancer Treat Rev. 1982 Dec;9 Suppl B:45-8. doi: 10.1016/s0305-7372(82)80035-2.
9
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).富含大麻素的 THC/CBD 口腔 cannabis 提取物用于预防化疗引起的恶心和呕吐的二级预防：一项先导和确证随机双盲安慰剂对照试验（CannabisCINV）的研究方案。
BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.
10
Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients.奈必洛尔与安慰剂治疗癌症患者化疗引起的恶心和呕吐的对比研究
Cancer Treat Rev. 1982 Dec;9 Suppl B:49-53. doi: 10.1016/s0305-7372(82)80036-4.

引用本文的文献

1
Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.大麻素在神经退行性疾病和中枢神经系统炎症性疾病治疗中的抗炎作用。
Int J Mol Sci. 2025 Jul 8;26(14):6570. doi: 10.3390/ijms26146570.
2
Prevalence of Self-Reported Adverse Effects to Cannabis by Older Canadians: A Cross-Sectional Analysis.加拿大老年人自我报告的大麻不良反应患病率：一项横断面分析。
Drugs Aging. 2025 Apr 23. doi: 10.1007/s40266-025-01206-4.
3
Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference.

本文引用的文献

1
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.大麻使用对欧洲各地精神病性障碍发病率差异的影响（欧盟基因-环境相互作用研究）：一项多中心病例对照研究。
Lancet Psychiatry. 2019 May;6(5):427-436. doi: 10.1016/S2215-0366(19)30048-3. Epub 2019 Mar 19.
2
Medical Use of Cannabinoids.医用大麻素
Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1.
3
Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study.
大麻素在所有适应症导致的中老年成年人不良事件：发病率差异的荟萃分析。
Age Ageing. 2024 Nov 1;53(11). doi: 10.1093/ageing/afae261.
4
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.大麻、大麻素与健康：关于风险和医学益处的证据综述
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):281-292. doi: 10.1007/s00406-024-01880-2. Epub 2024 Sep 19.
5
Marijuana use among community-dwelling older adults: A population-based study.社区居住的老年人中使用大麻的情况：一项基于人群的研究。
Int J Geriatr Psychiatry. 2024 Apr;39(4):e6086. doi: 10.1002/gps.6086.
6
Association Between Cannabis Use and Subjective Cognitive Decline: Findings from the Behavioral Risk Factor Surveillance System (BRFSS).大麻使用与主观认知衰退的关联：来自行为风险因素监测系统（BRFSS）的研究结果。
Curr Alzheimer Res. 2024;20(11):802-810. doi: 10.2174/0115672050301726240219050051.
7
Prevalence and Frequency of Cannabis Use Among Adults Ages 50-80 in the United States.50-80 岁美国成年人中大麻使用的流行率和频率。
Cannabis Cannabinoid Res. 2024 Feb;9(1):59-64. doi: 10.1089/can.2023.0056. Epub 2023 Nov 20.
8
Daily Δ-Tetrahydrocannabinol and Withdrawal Increase Dopamine D-D Receptor Heteromer to Mediate Anhedonia- and Anxiogenic-like Behavior Through a Dynorphin and Kappa Opioid Receptor Mechanism.每日服用Δ-四氢大麻酚及戒断会增加多巴胺D-D受体异聚体，通过强啡肽和κ阿片受体机制介导快感缺失和焦虑样行为。
Biol Psychiatry Glob Open Sci. 2022 Jul 30;3(3):550-566. doi: 10.1016/j.bpsgos.2022.07.003. eCollection 2023 Jul.
9
Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access.在一个没有合法大麻使用渠道的州，癌症患者和幸存者中使用大麻的流行率、模式和原因。
Support Care Cancer. 2023 Jun 29;31(7):429. doi: 10.1007/s00520-023-07881-6.
10
Resource use in the last year of life of prostate cancer patients-A register-based analysis.前列腺癌患者生命最后一年的资源利用——基于登记处的分析
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):438-443. doi: 10.1038/s41391-023-00685-z. Epub 2023 Jun 28.
首发精神病患者持续使用大麻与复发风险的相关性：一项基于观察性研究的准实验研究。
JAMA Psychiatry. 2016 Nov 1;73(11):1173-1179. doi: 10.1001/jamapsychiatry.2016.2427.
4
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.医用大麻素：系统评价和荟萃分析。
JAMA. 2015;313(24):2456-73. doi: 10.1001/jama.2015.6358.
5
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.大麻二酚和Δ9-四氢大麻酚对人脑功能和精神病理学的相反影响。
Neuropsychopharmacology. 2010 Feb;35(3):764-74. doi: 10.1038/npp.2009.184. Epub 2009 Nov 18.
6
Meta-analyses involving cross-over trials: methodological issues.涉及交叉试验的Meta分析：方法学问题。
Int J Epidemiol. 2002 Feb;31(1):140-9. doi: 10.1093/ije/31.1.140.